Literature DB >> 10640842

Clobetasol under hydrocolloid occlusion in psoriasis results in a complete block of proliferation and in a rebound of lesions following discontinuation.

J M Mommers1, P E van Erp, P C van De Kerkhof.   

Abstract

BACKGROUND: It is a well-established fact that very potent corticosteroids are highly effective in the treatment of psoriatic plaques, and that the addition of a hydrocolloid occlusive dressing (HCD) enhances its efficacy. It is known that topical steroids induce normal differentiation and diminish hyperproliferation during treatment of psoriatic plaques. These changes are reflected by an increase in keratin 10 (K10) and a decrease in keratin 6 (K6), respectively. However, the influence of class IV corticosteroids under HCD on K10 and K6 subpopulations has never been studied.
OBJECTIVE: The present study was performed to study quantitatively the influence of a class IV topical steroid under HCD on the dynamics of K10 and K6 subpopulations.
METHODS: In the present study, we treated moderately severe stable psoriatic plaques with clobetasol-17-propionate under HCD until clearance was achieved. We took biopsies prior to treatment, after clearance and at relapse. Using flow cytometry, we studied the dynamics of K10 and K6 subpopulations.
RESULTS: Prior to treatment, 41.8% of all cells expressed K6. After treatment-induced clearance, this proportion decreased to 1.2%, which is below the normal range. At relapse, pre-treatment levels were observed again. A trend to an increasing number of basal cells and an increase in the proliferative activity of these basal cells at relapse compared to the stable situation prior to treatment was observed.
CONCLUSION: We conclude that clobetasol under hydrocolloid occlusion induces virtually a total block of proliferation of the basal cell population and decreases hyperproliferation-associated keratins dramatically. Furthermore, based upon epidermal cell characteristics, we conclude that a rebound phenomenon occurs following discontinuation of therapy with clobetasol under hydrocolloid occlusion. Copyright (R) 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10640842     DOI: 10.1159/000018283

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

Review 1.  [Classical topical therapy of psoriasis].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2006-08       Impact factor: 0.751

2.  Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis.

Authors:  Mark Lebwohl; Norman Preston; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

3.  Ozone therapy promotes the differentiation of basal keratinocytes via increasing Tp63-mediated transcription of KRT10 to improve psoriasis.

Authors:  Lihua Gao; Jianhua Dou; Bo Zhang; Jinrong Zeng; Qingmei Cheng; Li Lei; Lina Tan; Qinghai Zeng; Shu Ding; Aiyuan Guo; Haipeng Cheng; Caifeng Yang; Ziqiang Luo; Jianyun Lu
Journal:  J Cell Mol Med       Date:  2020-03-13       Impact factor: 5.310

4.  Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis.

Authors:  M Lebwohl; D Thaçi; R B Warren
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.